Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tariquidar + Paclitaxel/Carboplatin in NSCLC
NCT00042302Phase 3Terminated
- Sponsor
- QLT Inc.
- Start
- Jun 2002
- Primary completion
- Jul 2003
- Modality
- Small Molecules
01
Overview
Phase 3, randomised, double-blind trial in non-small cell lung cancer (NSCLC) comparing Tariquidar + Chemo with Placebo + Chemo (2 arms). Primary endpoint: Overall Survival. Started Jun 2002; status: terminated.
02
Drugs
tariquidar
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT00042302.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00042302.